RT Journal Article
T1 AcetylacetonateBODIPY-Biscyclometalated Iridium(III) Complexes: Effective Strategy towards Smarter Fluorescent Photosensitizer Agents
A1 Palao Utiel, Eduardo
A1 Sola Llano, Rebeca
A1 Tabero Truchado, Andrea
A1 Manzano, Hegoi
A1 Rodríguez Agarrabeitia, Antonia
A1 Villanueva Oroquieta, Ángeles
A1 López Arbeloa, Íñigo María
A1 Martínez Martínez, Virginia
A1 Ortíz García, María Josefa
AB Biscyclometalated IrIII complexes involving boron-dipyrromethene (BODIPY)-based ancillary ligands, where the BODIPY unit is grafted to different chelating cores (acetylacetonate for Ir-1 and Ir-2, and bipyridine for Ir-3) by the BODIPY meso position, have been synthesized and characterized. Complexes with the BODIPY moiety directly grafted to acetylacetonate (Ir-1 and Ir-2) exhibit higher absorption coefficients (ϵ≈4.46×104 m−1 cm−1 and 3.38×104 m−1 cm−1 at 517 nm and 594 nm, respectively), higher moderate fluorescence emission (φfl≈0.08 and 0.22 at 528 nm and 652 nm, respectively) and, in particular, more efficient singlet oxygen generation upon visible-light irradiation (φΔ≈0.86 and 0.59, respectively) than that exhibited by Ir-3 (φΔ≈0.51, but only under UV light). Phosphorescence emission, nanosecond time-resolved transient absorption, and DFT calculations suggest that BODIPY-localized long-lived 3IL states are populated for Ir-1 and Ir-2. In vitro photodynamic therapy (PDT) activity studied for Ir-1 and Ir-2 in HeLa cells shows that such complexes are efficiently internalized into the cells, exhibiting low dark- and high photocytoxicity, even at significantly low complex concentration, making them potentially suitable as theranostic agents. © 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
PB Wiley
SN 0947-6539
YR 2017
FD 2017-07-26
LK https://hdl.handle.net/20.500.14352/18149
UL https://hdl.handle.net/20.500.14352/18149
LA eng
NO Manuscript Received: 24 MAR 2017; Accepted manuscript online: 19 MAY 2017; Version of Record online: 6 JUL 2017; Issue online: 26 JUL 2017
NO Ministerio de Economía y Competitividad (MINECO)
NO Ministerio de Ciencia e Innovación (MICINN)
NO Comunidad de Madrid
NO Gobierno vasco (España)
DS Docta Complutense
RD 1 sept 2024